Xanthic Biopharma (CSE:xTHC)

Xanthic Beverages, an Oregon-based beverage company, recently unveiled their flagship product, and it’s disruptive for the entire cannabis industry.


While other cannabinoid companies have been fighting over space on marijuana dispensary shelves, Xanthic Beverages has been rapidly taking over the mainstream marketplace.  Their flagship product, Xanthic CBD Water, is produced by a Pepsi independent bottler, and is currently being distributed by a network of Pepsi independent distributors in hundreds of retail locations throughout Washington and Oregon.

Xanthic CBD Water contains cannabidiol (CBD) derived from natural sources other than cannabis, making it the first commercially-available CBD exempt from the federal cannabis laws that currently hamper most mainstream retail cannabinoid distribution agreements in the U.S.  CBD is a non-psychoactive cannabinoid revered for a wide range of benefits.  CBD is so popular among athletes that in 2017 the World Anti-Doping Agency removed it from its list of banned substances.

Oregon has long been a cultural and industrial center for the cannabis industry.  Oregon became the first U.S. state to decriminalize marijuana in 1973, and in 1998 the Oregon Medical Marijuana Act was passed.  Oregon began allowing recreational marijuana sales in 2015, and now the scale of the industry has caught the attention of Wall Street.

In August, Constellation Brands, the maker of Corona and Modelo, announced an investment of $3.8 billion in Canopy Growth Corporation, a publicly-traded Canadian cannabis company.  And just this week Bloomberg reported that Coca-Cola is also monitoring the industry, with specific interest in CBD-infused beverages.  Arcview Market Research and BDS Analytics estimates the North American cannabis industry represents at least $100 billion in economic activity per year.  Total legal sales in North America already top $6 billion, with estimated legal sales of over $15 billion by 2020.

Xanthic Beverages was founded in January 2018 by Ryan Maxson and Ryan Stroud.  In March 2018 they signed a partnership agreement with Xanthic Biopharma Inc., a publicly-traded Canadian company [CSE:XTHC].

Says Stroud, “Some of the largest companies in the world in their respective categories have come to Oregon looking for ways to cash in on the cannabinoid opportunity.  Last fall an exec from one of those companies challenged us to make a cannabinoid product that a publicly-traded company like theirs could be involved in legally.  So we did.”

Maxson continues: “We also recognized that cottage-scale practices would not be sufficient to fill the scale of distribution pipeline we envisioned for ourselves, so we found a Pepsi-contracted bottler to produce our product.  Once distributors and large-chain retailers understood our capacity, they began to look at us a lot differently.”

Ryan Maxson is a fifth-generation family farmer who recognized early on the value of merchandising his products.  After high school, Maxson worked for two years in the West Wing of the White House before returning home and resuming his family’s long legacy in agriculture.  “When I first stepped out on my own as a farmer, kale was just beginning to trend,” he says, “so I grew a bunch of kale, but I knew all along it’s never the farmer who makes the strongest margins.”  It wasn’t long before he’d expanded his business model to include food processing and packaging.  And not long after, kale chips that he’d grown, processed, and packaged were being sold in thousands of retail locations across the U.S., as well as in three other countries.

When Oregon opened up its state-regulated cannabis market, Maxson saw the opportunity to take an even bigger step.  Maxson explains, “Because cannabis is still not federally legal, there is still a lot of mainstreaming and consolidation that hasn’t happened yet.  I wanted to take part in the opportunity by helping professionalize the industry, so I went looking for a business partner who had the cannabis industry piece, but who also had the professional piece.”

That’s when he met Ryan Stroud.  Stroud has been working in the cannabis industry for fifteen years.  He’s also a military veteran with a background that includes public policy development and Fortune 50 consulting.  Stroud explains, “After the military I was looking for another adventure.”  He ended up in Mendocino County, California, where he was introduced to Tim Blake, founder of the legendary Emerald Cup.  Says Stroud, “At that time under the California medical marijuana program many people were just beginning to move their production out into full sun, and there was demand for people who could operate in that unique environment.  Tim gave me the opportunity to be involved.”  His first season he was put to work as a gardener, and later running a trim crew.  The next season he was commissioned to oversee his own crop, and ended up placing in the Cup.

Stroud eventually moved to Portland where he earned a graduate degree and built a mainstream career.  “But I always kept a foot in cannabis,” he says.  “It was just something that I kept to myself.  I’d be working on a research project for a report to U.S. Congress, or I’d be helping an executive resolve a conflict, and then I’d go home and tend my medical grow.”

“But times have changed,” he continues.  “And the cannabinoid industry is no longer just about cannabis.  Whether a cannabinoid company focuses on medical efficacy or recreation, there are a number of different ways to produce and deliver cannabinoids.  Xanthic CBD Water is part of that evolution.”

Disclaimer:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no assurance that the Agreement with Xanthic Beverages will successfully produce benefits for Xanthic Biopharma Inc. Although such forward-looking statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances, except as required pursuant to applicable securities laws.

Related Links

http://www.xanthicbev.com

Click here to connect with Xanthic Biopharma (CSE:xTHC) for an Investor Presentation.

Source: www.prnewswire.com

  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less